Current state of immunotherapy for glioblastoma

Michael Lim; Yuanxuan Xia; Chetan Bettegowda; Michael Weller

doi:10.1038/s41571-018-0003-5

Keywords

TemozolomideMedicineImmunotherapyRadiation therapyGlioblastomaGliomaOncologyDiseaseImmune systemCancerChemotherapyInternal medicineImmunologyCancer research

Affiliated Institutions

Related Publications

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy , Aaron Mochizuki , Joey Orpilla +27 more

2019 Nature Medicine 1310 citations

Management of glioblastoma: State of the art and future directions

Aaron C. Tan , David M. Ashley , Giselle Y. López +3 more

Abstract Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. The...

2020 CA A Cancer Journal for Clinicians 1922 citations

Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide

Roger Stupp

PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma mult...

2002 Journal of Clinical Oncology 339 citations

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

David A. Reardon , Alba A. Brandes , Antonio Omuro +17 more

ClinicalTrials.gov Identifier: NCT02017717.

2020 JAMA Oncology 1314 citations

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

Thierry Gorlia , Martin J. van den Bent , Monika E. Hegi +9 more

A randomised trial published by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (...

2007 The Lancet Oncology 539 citations

Publication Info

Year: 2018
Type: review
Volume: 15
Issue: 7
Pages: 422-442
Citations: 1318
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Current state of immunotherapy for glioblastoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1318

OpenAlex

Cite This

APA Style

                            
                                
                                    Michael Lim, 
                                
                                    Yuanxuan Xia, 
                                
                                    Chetan Bettegowda
                                
                                et al.
                            
                            (2018). 
                            Current state of immunotherapy for glioblastoma. 
                            Nature Reviews Clinical Oncology
                            , 15
                            (7)
                            , 422-442.
                            https://doi.org/10.1038/s41571-018-0003-5
                        

Identifiers

DOI: 10.1038/s41571-018-0003-5